Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 known ✓ | P07900 | 1/20 | 0.41 |
| ▸ | POLA1 known ✓ | P09884 | 1/20 | 0.41 |
| ▸ | PPARG known ✓ | P37231 | 7/20 | 0.41 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 5/20 | 0.41 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.41 |
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.41 |
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.41 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.50 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.50 |
| ▸ | CES2 | O00748 | 3/20 | 0.42 |
| ▸ | CES1 | P23141 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.41 |
| ▸ | PPARD | Q03181 | 7/20 | 0.41 |
| ▸ | PPARA | Q07869 | 7/20 | 0.41 |
| ▸ | TSHR | P16473 | 4/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TLR2 | O60603 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10516686 | 1.00 | SPHK2 (0.50) | SPHK2SPHK1CES2CES1HSP90AA1 | |
| Methyl Alcohol SCHEMBL4439549 | 0.98 | SPHK2 (0.48) | SPHK2SPHK1CES2CES1HSP90AA1 | |
| SCHEMBL13491640 | 0.98 | SPHK2 (0.52) | SPHK2SPHK1CES2CES1HSP90AA1 | |
| Hydrochloric Acid SCHEMBL4529076 | 0.90 | — | — | |
| Hydrochloric Acid SCHEMBL351073 | 0.90 | SPHK2 (0.35) | SPHK2SPHK1TSHRALDH1A1 | |
| Hydrochloric Acid SCHEMBL3613960 | 0.90 | SPHK2 (0.35) | SPHK2SPHK1TSHRALDH1A1 | |
| Hydrochloric Acid SCHEMBL988664 | 0.90 | SPHK2 (0.35) | SPHK2SPHK1TSHRALDH1A1 | |
| Hydrochloric Acid SCHEMBL164104 | 0.90 | SPHK2 (0.35) | SPHK2SPHK1TSHRALDH1A1 | |
| SCHEMBL7221289 | 0.87 | — | — | |
| Hydrochloric Acid SCHEMBL432534 | 0.87 | TSHR (0.35) | SPHK2SPHK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9309214-B2 | Method for manufacturing neuraminic acid derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-04-12 | — | — | US | disclosed |
| US-9303008-B2 | Method for manufacturing neuraminic acid derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-04-05 | — | — | US | disclosed |
| US-20160052906-A1 | METHOD FOR MANUFACTURING NEURAMINIC ACID DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-02-25 | — | — | US | disclosed |
| US-20150376155-A1 | METHOD FOR MANUFACTURING NEURAMINIC ACID DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-12-31 | — | — | US | disclosed |
| US-20150376156-A1 | NEURAMINIC ACID DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-12-31 | — | — | US | disclosed |
| US-20150259314-A1 | METHOD FOR MANUFACTURING NEURAMINIC ACID DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-09-17 | — | — | US | disclosed |
| US-20140018417-A1 | METHOD FOR MANUFACTURING NEURAMINIC ACID DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-01-16 | — | — | US | disclosed |
| EP-2360156-B1 | Method for manufacturing neuraminic acid derivatives | DAIICHI SANKYO CO LTD (JP) | 2013-12-18 | — | — | EP | disclosed |
| US-8575370-B2 | Method for manufacturing neuraminic acid derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-11-05 | — | — | US | disclosed |
| US-20130197072-A1 | METHOD FOR MANUFACTURING NEURAMINIC ACID DERIVATIVES | DAIICHI SANKYO CO., LTD. (JP) | 2013-08-01 | — | — | US | disclosed |
| US-8455659-B2 | Method for manufacturing neuraminic acid derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-06-04 | — | — | US | disclosed |
| EP-2360151-B1 | Method for manufacturing neuraminic acid derivatives | DAIICHI SANKYO CO LTD (JP) | 2013-04-10 | — | — | EP | disclosed |
| EP-2132191-B1 | METHOD FOR MANUFACTURING NEURAMINIC ACID DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2013-02-20 | — | — | EP | disclosed |
| EP-2360135-B1 | Method for manufacturing neuraminic acid derivatives | DAIICHI SANKYO CO LTD (JP) | 2012-10-24 | — | — | EP | disclosed |
| EP-2360135-A1 | Method for manufacturing neuraminic acid derivatives | Daiichi Sankyo Company, Limited (JP) | 2011-08-24 | — | — | EP | disclosed |
| EP-2360151-A1 | Method for manufacturing neuraminic acid derivatives | Daiichi Sankyo Company, Limited (JP) | 2011-08-24 | — | — | EP | disclosed |
| EP-2360156-A1 | Method for manufacturing neuraminic acid derivatives | Daiichi Sankyo Company, Limited (JP) | 2011-08-24 | — | — | EP | disclosed |
| US-20100035947-A1 | METHOD FOR MANUFACTURING NEURAMINIC ACID DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-02-11 | — | — | US | disclosed |
| EP-2132191-A2 | METHOD FOR MANUFACTURING NEURAMINIC ACID DERIVATIVES | Daiichi Sankyo Company, Limited (JP) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008126943-A2 | METHOD FOR MANUFACTURING NEURAMINIC ACID DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160052906-A1 | METHOD FOR MANUFACTURING NEURAMINIC ACID DERIVATIVES | C9, CHRNA7, SCN7A | HSP90AA1 4043/4885POLA1 4549/4885PPARG 4780/4885 |
| US-20130197072-A1 | METHOD FOR MANUFACTURING NEURAMINIC ACID DERIVATIVES | C9, L1CAM, C3AR1 | HSP90AA1 3768/4885POLA1 4722/4885PPARG 4828/4885 |
| US-20150376156-A1 | NEURAMINIC ACID DERIVATIVES | NCDN, L1CAM, B3GNT2 | HSP90AA1 3652/4885POLA1 4134/4885PPARG 3860/4885 |
| US-20100035947-A1 | METHOD FOR MANUFACTURING NEURAMINIC ACID DERIVATIVES | NEFM, NCDN, NTRK1 | HSP90AA1 3927/4885POLA1 3811/4885PPARG 4716/4885 |
| US-20150259314-A1 | METHOD FOR MANUFACTURING NEURAMINIC ACID DERIVATIVES | C9, SCN7A, RTN4 | HSP90AA1 2790/4885POLA1 4462/4885PPARG 4847/4885 |
| US-20150376155-A1 | METHOD FOR MANUFACTURING NEURAMINIC ACID DERIVATIVES | NCDN, C9, BDNF | HSP90AA1 3557/4885POLA1 3851/4885PPARG 4370/4885 |
| US-20140018417-A1 | METHOD FOR MANUFACTURING NEURAMINIC ACID DERIVATIVES | NCDN, C9, BDNF | HSP90AA1 3395/4885POLA1 3860/4885PPARG 4385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.